The pharmacokinetics of the anticholinergic drug ethopropazine (ET) have been studied in the rat after intravenous (i.v.) and oral administration. After i.v. doses of 5 and 10 mg/kg ET HCl, mean +/- S.D. plasma AUC were 9836 +/- 2129 (n = 4 rats) and 13096 +/- 4186 ng h/mL (n = 5 rats), respectively
Urinary cyclophosphamide excretion in rats after intratracheal, dermal, oral and intravenous administration of cyclophosphamide
β Scribed by P. J. M. Sessink; P. H. H. van den Broek; R. P. Bos
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- English
- Weight
- 344 KB
- Volume
- 11
- Category
- Article
- ISSN
- 0260-437X
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
The urinary excretion of unmetabolized cyclophosphamide was studied in rats after intratracheal, dermal, oral and intravenous administration. Rats were given two doses of 1 mg kg^β1^ cyclophosphamide 48 h apart and urine was collected for 96 h after the first treatment.
With the help of a phosphorβspecific filter in a flame photometer attached to a gas chromatograph, low levels of cyclophosphamide were determined after derivatization with trifluoroacetic anhydride.
Cumulative excretion as a percentage of dose ranged from 4.0 to 6.9 after the first dose and 2.7 to 5.5 after the second dose. The highest rate of excretion after the second administration was observed in rats treated intratracheally, while cumulative excretion was higher (6.9%) after the first than after the second (2.7%) intravenous treatment. The most prolonged excretion was observed after dermal application.
π SIMILAR VOLUMES
## Abstract Circadian variations in the pharmacokinetics, tissue distribution and urinary excretion of nifedipine were examined in fasted rats after administering a single oral dose at three different dosing times (08:00 am, 16:00 pm, 00:00 am). The plasma concentrations, the areas under the plasma
The pharmacokinetics of a-dihydroergocriptine methane sulphonate in rats were investigated using an HPLC method for the detection of unchanged adihydroergocriptine (DHEK) in plasma, organs (kidneys, heart, lungs, spleen, liver, and brain), and urine. The plasma profile of DHEK obtained after intrave